Interestingly, KMT2D-mutant tumors exhibit enhanced immune infiltration in the tumor microenvironment, and KMT2D deficiency sensitizes multiple cancer types to anti-PD1 therapy by augmenting tumor immunogenicity (Wang et al., 2020). Here, KMT2D is linked to neoplasm.